Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Symptom Management Implementation of Patient Reported Outcomes in Oncology (SIMPRO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03850912
Recruitment Status : Not yet recruiting
First Posted : February 22, 2019
Last Update Posted : July 24, 2019
Sponsor:
Collaborators:
National Cancer Institute (NCI)
RTI International
Baptist Memorial Health Care Corporation
Dartmouth-Hitchcock Medical Center
Maine Medical Center
West Virginia University
Lifespan
Information provided by (Responsible Party):
Deborah Schrag, MD, Dana-Farber Cancer Institute

Brief Summary:
Deficits in the management of common symptoms cause substantial morbidity for cancer patients.Because the health care delivery system is structured to be reactive and not proactive, there are missed opportunities to optimize symptom control. Growth in Internet access and proliferation of smartphones has created an opportunity to re-engineer cancer care delivery. Electronic symptom tracking and feedback is a promising strategy to improve symptom control. Electronic patient reported outcome (ePRO) monitoring of cancer symptoms has been shown to decrease symptom burden, improve quality of life, reduce acute care and even extend survival. SIMPRO will use functioning ePRO prototypes to create and refine the electronic symptom management system eSyM

Condition or disease Intervention/treatment Phase
Other Cancer Gastrointestinal Cancer Thoracic Cancer Gynecologic Cancer Other: eSyM App Usage Other: SASS Questionnaire Not Applicable

Detailed Description:

A multi-disciplinary team of investigators from 6 health systems have formed the Symptom Management IMplementation of Patient Reported Outcomes in Oncology (SIMPRO) Research Center. SIMPRO will use functioning ePRO prototypes to create and refine the electronic symptom management system eSyM. eSyM is the name of the platform the team will refine, integrate, implement and evaluate. eSyM addresses each of the 4 evidence gaps by:

  • Implementing eSyM in cancer centers in small, rural or community-based systems.
  • Integrating eSyM into the EHR of the predominant vendor used nationwide.
  • Leveraging evidence-based tools, patient engagement, and population management.
  • Executing this work using the Consolidated Framework for Implementation Research across all phases to maximize the chances that eSyM and similar systems achieve their intended goals and decrease the morbidity of cancer treatment at a population level.

This project contains 4 activities:

  1. Obtain stakeholder feedback
  2. Build and deploy eSyM
  3. Pilot test eSyM
  4. Pragmatic stepped-wedge cluster randomized trial

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 18000 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Health Services Research
Official Title: SIMPRO Research Center: Integration and Implementation of PROs for Symptom Management in Oncology Practice
Estimated Study Start Date : September 1, 2019
Estimated Primary Completion Date : May 31, 2023
Estimated Study Completion Date : September 30, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Palliative Care

Arm Intervention/treatment
No Intervention: Activity 1: Stakeholder Feedback

Obtain stakeholder feedback to inform eSyM finalization and implementation from:

  • patient advisory councils
  • health system leaders
  • clinicians
  • clinic support staff/administration
  • IT/Informatics
No Intervention: Activity 2: eSym Build
  • Build and deploy eSyM
  • Finalize training materials based on findings from stakeholder engagement
Experimental: Activity 3: Pilot Test eSyM App

Pilot testing of the eSyM app will include:

  • Activity 3a (eSyM app usage by patients)
  • Activity 3b (User acceptability testing)
  • Activity 3c (Medical record abstraction)
Other: eSyM App Usage
Patients (and/or proxy) will report their cancer-related symptoms and receive tailored feedback via eSyM

Experimental: Activity 4: eSyM+ Participants
  • These patients (and/or proxy) will report their symptoms in eSyM
  • A subset of these patients will be asked to complete a research questionnaire called the "SASS Questionnaire (eSyM+ version)"
  • A medical record abstraction will be completed for ALL eSyM+ patients
Other: eSyM App Usage
Patients (and/or proxy) will report their cancer-related symptoms and receive tailored feedback via eSyM

Other: SASS Questionnaire
A subset of eSyM+ and eSyM- patients will be asked to complete a research questionnaire called the "SASS Questionnaire" asking about their Self-efficacy, Attainment of information needs, Symptom burden, and Satisfaction with care (see PROMIS, CAHPS, IAM/AIM question banks - Appendices C through G). The questionnaire will stop being administered once 1800 total surveys have been received.

Experimental: Activity 4: eSyM- Participants
  • These patients (and/or proxy) will NOT report their symptoms in eSyM
  • A subset of these patients will be asked to complete a research questionnaire called the "SASS Questionnaire (eSyM- version)"
  • A medical record abstraction will be completed for ALL eSyM- patients
Other: SASS Questionnaire
A subset of eSyM+ and eSyM- patients will be asked to complete a research questionnaire called the "SASS Questionnaire" asking about their Self-efficacy, Attainment of information needs, Symptom burden, and Satisfaction with care (see PROMIS, CAHPS, IAM/AIM question banks - Appendices C through G). The questionnaire will stop being administered once 1800 total surveys have been received.




Primary Outcome Measures :
  1. 'Emergency Department - Treat and Release' (EDTR) Rate at 30-days [ Time Frame: 30 days ]

    The primary study outcome of the stepped wedge cluster RCT is the EDTR rate. This outcome will be defined in relation to the date of discharge from hospital (surgical oncology) or the initiation date of a new intravenous chemo regimen (medical oncology). The investigators will evaluate the # of EDTR visits for patients using the eSyM app.

    30-day EDTR rates are estimated to vary between 8% to 15% for the control group. The investigators hypothesize that EDTR rates will be 3-4% lower in the eSyM+ group. Control group rates were estimated based on EDTR rates derived from HCUP data, institutional data and early phase analyses from CMMI's Oncology Care Model for Baptist Memorial, the only Oncology Care Model participant among our 6 sites.



Secondary Outcome Measures :
  1. Patients' outcomes, indicated by levels of self-efficacy and symptom burden, at day 30 of eSyM usage [ Time Frame: One time survey (30-60 days after surgery or first dose of chemo) ]
    Patients (both Surg Onc and Med Onc) from each of the 6 sites will be surveyed in the period before and after rollout according to the stepped wedge design schema. Assuming a 75% response rate, the investigators expect to survey 400 patients per site (2400 total) to obtain 300 (1800 total) responses split evenly between eSyM+ and eSyM- subjects. Additional survey participants can readily be identified if the 75% response rate is not achieved. Yost and Cella have reported minimally important difference (MID) ranges for five PROMIS domains including fatigue, pain, depression, anxiety, and physical functioning217, 130 Cella recommends using 0.5 SD as the MID for PROMIS scales218,219.

  2. Patients' satisfaction with their cancer care at 30-days post-chemo start or post-surgery: AHRQ's CAHPS Analysis Program [ Time Frame: One time survey (30-60 days after surgery or first dose of chemo) ]
    The investigators will use the AHRQ's CAHPS Analysis Program to compare scores for eSyM+ and eSyM-, adjusting for case mix. Table Aim 2d (in the protocol) shows differences in satisfaction scores the investigators can detect with 80% power. For example, with 360 patients (e.g., those who have GI surgery) the investigators have >80% power to detect effect size >0.44, a meaningful difference in CAHPS scores. Patients will complete a subset of the CAHPS Cancer Care Survey. Items assessed will include: cancer care delivery, patient experience, and patient satisfaction. Responses will be assessed through the following options: a) (Never, Sometimes, Usually, Always) b) (Yes, definitely, Yes, somewhat, No) c) 0-10.

  3. eSyM sustainability at the patient, clinic and health system level [ Time Frame: 1-year medical record abstraction ]
    The investigators will be evaluating patient adoption rates and clinician usage rates by analyzing EHR data based on eSyM utilization patterns. Appropriateness and acceptability will be ascertained using Weiner's IAM and AIM surveys (8-items total, less than 3 minutes to complete) which will be administered along with CAHPS surveys. Appropriateness and acceptability ratings will be defined based on the % of respondents who "agree" or "completely agree" with the survey items compared to the % who are neutral, disagree, or completely disagree and characterized using descriptive statistics.81

  4. Impact on initiation of adjuvant chemotherapy and chemotherapy duration assessed at 1 year [ Time Frame: 1-year medical record abstraction ]

    The investigators will be using the EMR to evaluate the timing of first dose to the last dose of a specific chemotherapy regimen. The investigators expect that patients exposed to eSyM may be able to: 1) initiate adjuvant therapy sooner; 2) remain on their chemotherapy regimens for longer duration. These time intervals are straightforward to measure from EHR encounter and date fields.

    For medical oncology patients, the outcome is time from the first dose to the last dose of a specific regimen. The investigators will censor follow-up at 1 year. The investigators will use generalized linear mixed-effect models to compare treatment duration for eSyM+ vs. eSyM- patients. For surgical oncology patients, the denominator population consists of patients who receive any adjuvant chemotherapy within 6 postoperative months. Tumor registry stage distribution at our 6 sites indicates that this will be 202 patients per site or 1212 in total.


  5. Sustainability of ePRO symptom management within a health system [ Time Frame: 1-year medical record abstraction ]
    The investigators will evaluate sustainability at the patient, clinic and health system level using simple rates and proportions. To evaluate sustainability, the investigators will examine the consequences of withdrawing grant-funded nursing support for symptom management in the post-implementation period. The investigators will compare outcomes from Period 6 (study month 45-50, all sites eSyM+) and the post-Implementation (Post-I; study months 51-56). Sites are trained and empowered to manage eSyM autonomously without research study staff. Then, during post-implementation, dedicated nursing support to monitor eSyM is tapered in half the sites (see Figure C2). To examine whether backing off on the study support attenuates the effect, the investigators will perform difference in difference analysis.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Activity 1 Population:

  • Age ≥ 18 years
  • The potential stakeholders are: patient advisory council members, health system leaders, clinicians, clinic support staff/administration, IT/Informatics staff

Activity 3 Population:

  • Age ≥ 18 years
  • Priority population will be patients who meet one of the following:

    • Diagnosis of thoracic cancer [lung or bronchus] AND is inpatient following thoracic cancer surgery.
    • Diagnosis of gastrointestinal cancer [colorectal, pancreas, liver/biliary, esophagus,or gastric] AND is inpatient following gastrointestinal cancer surgery.
    • Diagnosis of gynecologic cancer [ovary, uterus, or cervix] AND is inpatient following gynecologic cancer surgery.
    • Diagnosis of thoracic cancer [lung or bronchus] AND scheduled to start a new palliative chemotherapy regimen for thoracic cancer.
    • Diagnosis of gastrointestinal cancer [colorectal, pancreas, liver/biliary, esophagus,or gastric] AND scheduled to start a new palliative chemotherapy regimen for gastrointestinal cancer.
    • Diagnosis of gynecologic cancer [ovary, uterus, or cervix] AND scheduled to start a new palliative chemotherapy regimen for gynecologic cancer.
  • Total population allowed to use eSyM:

    • Any cancer patient at any participating site.

Activity 4 Population:

  • Age ≥ 18 years
  • Priority population will be patients who meet one of the following:

    • Diagnosis of thoracic cancer [lung or bronchus] AND is inpatient following thoracic cancer surgery.
    • Diagnosis of gastrointestinal cancer [colorectal, pancreas, liver/biliary, esophagus,or gastric] AND is inpatient following gastrointestinal cancer surgery.
    • Diagnosis of gynecologic cancer [ovary, uterus, or cervix] AND is inpatient following gynecologic cancer surgery.
    • Diagnosis of thoracic cancer [lung or bronchus] AND scheduled to start a new palliative chemotherapy regimen for thoracic cancer.
    • Diagnosis of gastrointestinal cancer [colorectal, pancreas, liver/biliary, esophagus,or gastric] AND scheduled to start a new palliative chemotherapy regimen for gastrointestinal cancer.
    • Diagnosis of gynecologic cancer [ovary, uterus, or cervix] AND scheduled to start a new palliative chemotherapy regimen for gynecologic cancer.
  • Total population allowed to use eSyM:

    • Any cancer patient at any participating site.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03850912


Contacts
Layout table for location contacts
Contact: Deborah Schrag, MD, MPH 617-582-8301 deb_schrag@dfci.harvard.edu

Locations
Layout table for location information
United States, Maine
Maine Medical Center Not yet recruiting
Portland, Maine, United States, 04101
Contact: Scot Remick, MD         
Principal Investigator: Scot Remick, MD         
United States, Massachusetts
Dana Farber Cancer Institute Not yet recruiting
Boston, Massachusetts, United States, 02115
Contact: Christine Cronin    617-632-3784    christine_cronin@dfci.harvard.edu   
Principal Investigator: Deborah Schrag, MD, MPH         
United States, New Hampshire
Dartmouth-Hitchcock Medical Center Not yet recruiting
Lebanon, New Hampshire, United States, 03756
Contact: Sandra Wong, MD         
Principal Investigator: Sandra Wong, MD         
United States, Rhode Island
Lifespan Not yet recruiting
Providence, Rhode Island, United States, 02905
Contact: Don Dizon, MD         
Principal Investigator: Don Dizon, MD         
United States, Tennessee
Baptist Memoiral HealthCare Not yet recruiting
Memphis, Tennessee, United States, 38120
Contact: Raymond Osarogiagbon, MD         
Principal Investigator: Raymond Osarogiagbon, MD         
United States, West Virginia
West Virginia University Medical Center Not yet recruiting
Morgantown, West Virginia, United States, 26506
Contact: Hannah Hazard-Jenkins, MD         
Principal Investigator: Hannah Hazard-Jenkins, MD         
Sponsors and Collaborators
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
RTI International
Baptist Memorial Health Care Corporation
Dartmouth-Hitchcock Medical Center
Maine Medical Center
West Virginia University
Lifespan
Investigators
Layout table for investigator information
Principal Investigator: Deborah Schrag, MD, MPH Dana-Farber Cancer Institute

Publications:

Layout table for additonal information
Responsible Party: Deborah Schrag, MD, Principal Investigator, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier: NCT03850912     History of Changes
Other Study ID Numbers: 18-734
1UM1CA233080-01 ( U.S. NIH Grant/Contract )
First Posted: February 22, 2019    Key Record Dates
Last Update Posted: July 24, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research data set used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Time Frame: Data can be shared no earlier than 1 year following the date of publication
Access Criteria: DFCI - Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Deborah Schrag, MD, Dana-Farber Cancer Institute:
Other Cancer
Digital health
Patient reported outcomes
Symptom management

Additional relevant MeSH terms:
Layout table for MeSH terms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases